BIO-TECH Systems, Inc. - Report #170: The U.S. Market for Brachytherapy Products

Market Research in the Healthcare Field with Expertise in Medical Imaging and Radioisotopes

Bio-Tech Systems, Inc. - 4167 West Pinecrest Circle - Las Vegas, Nevada 89121 phone: (702) 456-7608 - fax: (702) 456-2189


	HOME

	ABOUT BIO-TECH SYSTEMS

	AUTHOR'S C.V.

	BREAKING MARKET NEWS

	REPORT #270 The U.S. Market for Diagnostic Radiopharmaceuticals New! Released in Nov. 2007!

	REPORT #260 The U.S. Market for Medical Imaging Contrast Media New! Released in Mar. 2007!

	REPORT #240 The Market for PET Radiopharmaceuticals & PET Imaging

	REPORT #230 The World Market for Therapeutic Radiopharmaceuticals

	REPORT #170 The U.S. Market for Brachytherapy Products
Report Contents
Partial List of Exhibits

	ORDERS

	NEWS RELEASES

	CONTACT US

THE U.S. MARKET FOR BRACHYTHERAPY PRODUCTS

BIO-TECH SYSTEMS INC. announces the publication of:

BIO-TECH Report #170, The U.S. Market for Brachytherapy Products

The Brachytherapy Report Includes:

Current and Future Market for Prostate Seed Implants
Growth of Endovascular Radiation Market for Restenosis
Markets for Post-Surgical Brachytherapy Products
New Products and Markets for Oncology Applications
Technological Trends and Competitive Challenges
Market Assessment and Sales Forecasts to 2008

The report analyzes market performance and continuing opportunities in prostate seed implants, growth markets for endovascular brachytherapy, new interventional post-surgical brachytherapy devices for brain cancer, breast cancer and other cancers with high recurrence rate. The report also discusses market prospects in emerging technologies including irradiated microsphere infusion for primary and secondary liver cancer, and plaque radiotherapy for intraocular tumors. The report has a strong focus on new products and technology and emerging market opportunities. Many new brachytherapy products have been introduced recently, with rapid growth in procedure volume. This has provided a good opportunity for evaluating performance and forecasting future growth.

Prostate seeds implants have continued to demonstrate effectiveness and are now used to treat 25% of all newly diagnosed prostate cases. Designs have been improved, facilitating more accurate placement and better treatment planning. The market for endovascular radiation has also progressed rapidly since the first products were approved in 2001. There are now three different devices offered, with approved indications for in-stent restenosis. Manufacturers are already introducing second-generation devices, significantly extending the range of endovascular radiation procedures. New devices include smaller diameter catheters and catheters for peripheral-vascular lesions. Catheters for treating dialysis shunts are also being developed.

In another segment, post-surgical brachytherapy has been successfully introduced with dedicated devices for treating brain cancer and breast cancer. Market response has been very positive, stimulating further growth and development of new applications in head and neck cancer, bladder cancer, uterine cancer and other cancers where the resection cavity is accessible for placement of the devices. In other applications, irradiated microsphere infusion received a large boost recently with the approval of a new product for treating primary and secondary liver cancer. This has significantly increased the survival rate for patients with metastatic disease that has spread to the liver. All these developments in brachytherapy have encouraged investment in new technology, creating a good platform for future growth.

Market Analysis and Future Prospects
US sales of brachytherapy products were $321 million in 2002 and should grow to $1,376 million by 2008. The market for implantable prostate seeds reached $193 million in 2002 due to effective promotion and utilization of these products. New companies have entered the field and competition has increased. However, there are still good growth prospects, with forecast sales of $308 million by 2008. Endovascular brachytherapy sales were $96 million in 2002, with forecast growth to $317 million by 2008. Although there will be competition from drug eluting stents, the positive performance of these devices will help maintain market growth. Rapid introduction of new technology with reduced regulatory delays will also help this market. Post-surgical brachytherapy was introduced in 2001, with sales of $16 million in 2002. Considering the potentials, particularly in breast cancer, this market should grow to $578 million by 2008. These devices will reduce treatment time and accelerate recovery for many patients. The market for irradiated microsphere infusion products for liver cancer and related applications should increase rapidly from $3 million in 2002 (partial year sales) to $157 million by 2008. About 60% of this will be derived from products for treating liver cancer and 40% from new indications that will emerge during the forecast period. Procedure volume will reach about 16,000 by 2008, which is a conservative estimate based on the incidence and prevalence of primary and secondary liver cancer and the therapeutic effectiveness of this modality.

Please follow one of the links below, or on the left, to find out more information about BIO-TECH Report #170. If you are interested in purchasing BIO-TECH Report #170, please follow this link to our Online Order Form.

To download a detailed Table of Contents (TOC) for BIO-TECH Report #170, please click on one of the two links below. The documents are a Microsoft Word 97-2000 file and an Adobe Acrobat 6 PDF file.

Download TOC in MS Word format (124KB)

Download TOC in Adobe PDF format (45KB)

Report Contents | Partial List of Exhibits

Report #170 Home Page

Download Report #170 Table of Contents:

BTSI170.doc -OR-

BTSI170.pdf

Send this page to a friend